XNCR Stock Overview
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Xencor, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.54 |
| 52 Week High | US$28.96 |
| 52 Week Low | US$16.49 |
| Beta | 0.76 |
| 1 Month Change | 16.13% |
| 3 Month Change | 21.22% |
| 1 Year Change | -12.00% |
| 3 Year Change | -41.93% |
| 5 Year Change | -31.31% |
| Change since IPO | 182.25% |
Recent News & Updates
Recent updates
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Mar 27
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Feb 27Xencor: Standing Out With XmAb Technology
Feb 03Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
Jan 05Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
Nov 13Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
Nov 10Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Aug 08Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon
Aug 12Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M
Aug 03Xencor: Capital-Efficient Platform Tech Play With A Lot Going On
Jun 03Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate
Feb 18Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts
Aug 06It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year
Jun 20Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Apr 02Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)
Mar 06Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook
Mar 02Are Investors Undervaluing Xencor, Inc. (NASDAQ:XNCR) By 39%?
Feb 26Shareholder Returns
| XNCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.4% | 0.5% | 2.7% |
| 1Y | -12.0% | 3.4% | 26.0% |
Return vs Industry: XNCR underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: XNCR underperformed the US Market which returned 25% over the past year.
Price Volatility
| XNCR volatility | |
|---|---|
| XNCR Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XNCR has not had significant price volatility in the past 3 months.
Volatility Over Time: XNCR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 280 | Bassil Dahiyat | www.xencor.com |
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types.
Xencor, Inc. Fundamentals Summary
| XNCR fundamental statistics | |
|---|---|
| Market cap | US$1.46b |
| Earnings (TTM) | -US$126.09m |
| Revenue (TTM) | US$168.34m |
8.6x
P/S Ratio-11.5x
P/E RatioIs XNCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XNCR income statement (TTM) | |
|---|---|
| Revenue | US$168.34m |
| Cost of Revenue | US$253.60m |
| Gross Profit | -US$85.26m |
| Other Expenses | US$40.83m |
| Earnings | -US$126.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | -50.65% |
| Net Profit Margin | -74.90% |
| Debt/Equity Ratio | 3.1% |
How did XNCR perform over the long term?
See historical performance and comparison